Ipamorelin is widely regarded as the safest and most selective growth hormone releasing peptide (GHRP) available. Unlike GHRP-6 or GHRP-2, clinical studies show it produces very few side effects at research doses. Here's what the data actually says.
Why Ipamorelin Has Fewer Side Effects Than Other GHRPs
Most GHRPs stimulate multiple receptors beyond the GH secretagogue receptor (GHS-R). GHRP-6 strongly activates ghrelin receptors in the hypothalamus, causing significant appetite stimulation. GHRP-2 elevates cortisol and prolactin alongside GH. Ipamorelin is highly selective — it binds to GHS-R with minimal off-target effects on cortisol, prolactin, or ACTH.
In the original Phase 1 trial by Raun et al. (1998), NNC 26-0161 (ipamorelin) was specifically noted for its "high GH selectivity without concomitant rise in ACTH, cortisol, prolactin, FSH, or LH."
Common Side Effects (Mild)
Water retention/bloating: The most frequently reported side effect. GH elevation increases renal sodium retention and water retention in soft tissues. Typically mild and subsides as the body adapts. Can be managed by reducing dose or frequency.
Mild fatigue or tiredness: Especially when dosed before bed, the GH pulse can cause drowsiness. This is actually desirable for sleep-based protocols.
Tingling or numbness in extremities: Mild carpal tunnel-like symptoms from increased IGF-1, common to all GH-stimulating compounds. Usually dose-dependent and resolves with dose reduction.
Headache: Occasional mild headaches, especially when starting. Usually transient.
Side Effects at Higher Doses
At doses significantly above the typical 100-200mcg range, side effects can increase:
Flushing (face redness): Transient skin flushing can occur immediately after injection, lasting minutes.
Increased appetite: Some hunger stimulation occurs at higher doses, though far less than GHRP-6.
Joint aches: Elevated GH and IGF-1 can cause mild joint pain, especially in the hands and feet.
What Ipamorelin Does NOT Do
Notably absent from ipamorelin's side effect profile (confirmed in clinical studies):
- No significant cortisol elevation (unlike GHRP-2)
- No significant prolactin elevation
- No significant appetite stimulation (unlike GHRP-6)
- No thyroid axis disruption
- No testosterone suppression
- No natural GH suppression (pulsatile use preserves pituitary sensitivity)
Long-Term Safety
Ipamorelin has been studied in humans in clinical trials for weight management (Phase 2). The safety profile across 12+ week studies has been favorable, with no serious adverse events attributable to ipamorelin at research doses.
The main theoretical long-term concern with any GH secretagogue is the potential for receptor desensitization with continuous use. To minimize this, most protocols cycle 5 days on, 2 days off, or take 4-6 week breaks every few months.
Key Takeaways
Ipamorelin has an exceptionally clean side effect profile compared to other GHRPs. The most common effects — water retention and mild fatigue — are manageable and typically transient. The absence of cortisol, prolactin, and appetite-stimulating effects makes it the preferred GHRP for most research protocols.